{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:55:40Z","timestamp":1765526140049,"version":"3.48.0"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_dmpt-2018-0002_s_999_w2aab2b8c21b1b7b1aab1c16b1Aa\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Relapsing polychondritis (RP) is a rare autoimmune disorder, and myelodysplastic syndrome (MDS) is accompanied by RP at variable rates. Herein, we report a case with RP and MDS who responded dramatically to 5-azacitidine for MDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2018-0002_s_998_w2aab2b8c21b1b7b1aab1c16b2Aa\">\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>With conventional immunosuppressive treatment, our patient had several episodes of different side effects, including infections. With the diagnosis of MDS and initiation of azacitidine treatment, all the manifestations of RP disappeared, and remission was achieved for MDS. Although he had relapses of either RP or MDS after several years of azacitidine treatment, all relapses were controlled well with the initiation of azacitidine treatment every time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2018-0002_s_997_w2aab2b8c21b1b7b1aab1c16b3Aa\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Azacitidine should be kept in mind as a treatment option for RP patients with MDS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/dmpt-2018-0002","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T18:16:22Z","timestamp":1525198582000},"page":"105-108","source":"Crossref","is-referenced-by-count":10,"title":["Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature"],"prefix":"10.1515","volume":"33","author":[{"given":"Abdulsamet","family":"Erden","sequence":"first","affiliation":[{"name":"Hacettepe University Faculty of Medicine , Department of Internal Medicine, Division of Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2260-4660","authenticated-orcid":false,"given":"Emre","family":"Bilgin","sequence":"additional","affiliation":[{"name":"Hacettepe University Faculty of Medicine , Department of Internal Medicine, Division of Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[{"name":"Hacettepe University Faculty of Medicine , Department of Internal Medicine, Division of Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Sar\u0131","sequence":"additional","affiliation":[{"name":"Hacettepe University Faculty of Medicine , Department of Internal Medicine, Division of Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berkan","family":"Arma\u011fan","sequence":"additional","affiliation":[{"name":"Hacettepe University Faculty of Medicine , Department of Internal Medicine, Division of Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya","family":"B\u00fcy\u00fcka\u015f\u0131k","sequence":"additional","affiliation":[{"name":"Hacettepe University Faculty of Medicine , Department of Internal Medicine, Division of Hematology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[{"name":"Hacettepe University Faculty of Medicine , Department of Internal Medicine, Division of Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,5,1]]},"reference":[{"key":"2025121207100437630_j_dmpt-2018-0002_ref_001_w2aab2b8c21b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Okamoto T, Okada M, Mori A, Takatsuka H, Wada H, Tamura A, et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 1997;66:345\u201351.","DOI":"10.1016\/S0925-5710(97)00042-X"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_002_w2aab2b8c21b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Chang SJ, Lu CC, Chung YM, Lee SS, Chou CT, Huang DF. Laryngotracheal involvement as the initial manifestation of relapsing polychondritis. J Chin Med Assoc 2005;68:279\u201382.","DOI":"10.1016\/S1726-4901(09)70151-0"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_003_w2aab2b8c21b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"McAdam LP, O\u2019Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976;55:193\u2013215.","DOI":"10.1097\/00005792-197605000-00001"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_004_w2aab2b8c21b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Fozza C, Longinotti M. The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers. Leuk Res 2013;37:201\u20133.","DOI":"10.1016\/j.leukres.2012.11.007"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_005_w2aab2b8c21b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Levesque H, et al. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken) 2011;63:1188\u201394.","DOI":"10.1002\/acr.20504"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_006_w2aab2b8c21b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Fozza C, Crobu V, Isoni MA, Dore F. The immune landscape of myelodysplastic syndromes. Crit Rev Oncol Hematol 2016;107:90\u20139.","DOI":"10.1016\/j.critrevonc.2016.08.016"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_007_w2aab2b8c21b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 2016;55:291\u2013300.","DOI":"10.1093\/rheumatology\/kev294"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_008_w2aab2b8c21b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Hebbar M, Hebbar-Sav\u00e9an K, Fenaux P. Maladies syst\u00e9miques au cours des syndromes my\u00e9lodysplasiques. Rev Med Interne 1995;16:897\u2013904.","DOI":"10.1016\/0248-8663(96)80810-1"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_009_w2aab2b8c21b1b7b1ab2b1b9Aa","unstructured":"Piette JC, Papo T, Chavanon P, Houng DL, Frances C, Godeau P. Myelodysplasia and relapsing polychondritis. J Rheumatol 1995;22:1208\u20139."},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_010_w2aab2b8c21b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Frances C, el Rassi R, Laporte JL, Rybojad M, Papo T, Piette JC. Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center. Medicine (Baltimore) 2001;80:173\u20139.","DOI":"10.1097\/00005792-200105000-00003"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_011_w2aab2b8c21b1b7b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Anderson L, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100:822\u20138.","DOI":"10.1038\/sj.bjc.6604935"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_012_w2aab2b8c21b1b7b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Bj\u00f6rkholm M, Hultcrantz M, Derolf \u00c5R, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011;29:2897\u2013903.","DOI":"10.1200\/JCO.2011.34.8540"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_013_w2aab2b8c21b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Wilson AB, Neogi T, Prout M, Jick S. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the general practice research database. Cancer Epidemiol 2014;38:544\u20139.","DOI":"10.1016\/j.canep.2014.08.003"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_014_w2aab2b8c21b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Silverman RS. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 2001;6(suppl 5):8\u201314.","DOI":"10.1634\/theoncologist.6-suppl_5-8"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_015_w2aab2b8c21b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Fraison JB, Makinian A, Gringnano E, Kahn JE, Arlet JB, Dexaux O, et al. Efficacy of azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res 2016;43:13\u20137.","DOI":"10.1016\/j.leukres.2016.02.005"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_016_w2aab2b8c21b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, Bontkes HJ. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011;153:568\u201381.","DOI":"10.1111\/j.1365-2141.2011.08683.x"},{"key":"2025121207100437630_j_dmpt-2018-0002_ref_017_w2aab2b8c21b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Michet CJ Jr, McKenna CH, Luthra HS, O\u2019Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med 1986;104:74\u201378.","DOI":"10.7326\/0003-4819-104-1-74"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/dmdi.2018.33.issue-2\/dmpt-2018-0002\/dmpt-2018-0002.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2018-0002\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2018-0002\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:52:21Z","timestamp":1765525941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2018-0002\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,5,4]]},"published-print":{"date-parts":[[2018,6,27]]}},"alternative-id":["10.1515\/dmpt-2018-0002"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2018-0002","relation":{},"ISSN":["2363-8915","2363-8907"],"issn-type":[{"type":"electronic","value":"2363-8915"},{"type":"print","value":"2363-8907"}],"subject":[],"published":{"date-parts":[[2018,5,1]]}}}